Skip to main content
Premium Trial:

Request an Annual Quote

Perlegen Nabs $74M in Private Stock Placement; Cash to Flesh Out Drug Pipeline

NEW YORK, Feb. 28 (GenomeWeb News) - Perlegen Sciences has closed $74 million in a private placement of its Series D Preferred Stock with new and existing investors, the company said today.


The company will use the equity financing "to continue in-licensing and developing a ... pipeline of late-stage drugs, exploiting Perlegen's ability to target the right drugs to the right patients," Robert Middlebrook, chief corporate development officer of Perlegen, said in a statement.


CSK Venture Capital led the financing, followed by new investors Brookside Capital, an affiliate of Bain Capital; Mizuho Securities; Glynn Capital Management; CapeSecurities; and "several other" USand European institutional investors.


Previous investors also participating in the financing included Affymetrix, Alex Zaffaroni, Maverick Capital, Lombard Odier Darier Hentsch & Cie, Zesiger Capital, Sano Ventures, BSI SA, MPM BioEquities, SB Life Sciences, Unilever Ventures, Biofrontier Partners, Private Life Biomed, and CMEA Ventures.

The Scan

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.

Team Presents Cattle Genotype-Tissue Expression Atlas

Using RNA sequences representing thousands of cattle samples, researchers looked at relationships between cattle genotype and tissue expression in Nature Genetics.

Researchers Map Recombination in Khoe-San Population

With whole-genome sequences for dozens of individuals from the Nama population, researchers saw in Genome Biology fine-scale recombination patterns that clustered outside of other populations.

Myotonic Dystrophy Repeat Detected in Family Genome Sequencing Analysis

While sequencing individuals from a multi-generation family, researchers identified a myotonic dystrophy type 2-related short tandem repeat in the European Journal of Human Genetics.